V-Bio Ventures
Investor profile
Venture capital
Deals
7
distinct rounds
Companies
7
backed
Active span
2018–2022
5 yrs
Total round €
€222M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- FundPlus2
- GIMV2
- Seroba Life Sciences2
- 3B Future Health Fund1
- Ackermans & van Haaren1
- Advent France Biotechnology1
- AIF1
- BioMedPartners1
- BNP Paribas Fortis Private Equity1
- CDP Venture Capital1
- Claris Ventures1
- eureKARE1
- Evolution Ventures1
- Flanders Future Techfund (FFTF)1
- Forbion1
- Go Capital1
- HealthCap1
- IDInvest Partners1
- Indaco Venture Partners1
- INKEF Capital1
- Jeito Capital1
- KU Leuven Gemma Frisius Fund1
- Kurma Partners1
- Mérieux Equity Partners1
- Novo Holdings1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Precirix | Belgium | 1 | €80M |
| Camel-IDS | Belgium | 1 | €37M |
| AstriVax | Belgium | 1 | €30M |
| Sibylla Biotech | Italy | 1 | €23M |
| Coave Therapeutics | France | 1 | €21M |
| Agomab Therapeutics | Belgium | 1 | €21M |
| Animab | Belgium | 1 | €10M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Precirix | Series B | €80M | 2022-03 |
| Camel-IDS | Series A | €37M | 2018-11 |
| AstriVax | Seed | €30M | 2022-08 |
| Sibylla Biotech | Series A | €23M | 2022-10 |
| Coave Therapeutics | Series B | €21M | 2021-07 |
| Agomab Therapeutics | Series A | €21M | 2019-03 |
| Animab | Series A | €10M | 2022-11 |